PGDx’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

PGDx is a biopharmaceutical company that develops and commercializes liquid biopsy genome testing products for the treatment of cancer. Read more

PGDx is a biopharmaceutical company that develops and commercializes liquid biopsy genome testing products for the treatment of cancer. Read more

Megan Bailey's photo - CEO of PGDx

CEO

Megan Bailey

CEO Approval Rating

82/100

Founded:

2010

Status:

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Biocept is seen as one of PGDx's biggest rivals. Biocept is headquartered in San Diego, California, and was founded in 1997. Like PGDx, Biocept also works within the Biotechnology sector. Biocept generates 35% the revenue of PGDx.

Invitae is seen as one of PGDx's top competitors. Invitae was founded in 2010, and its headquarters is in San Francisco, California. Invitae operates in the Biotechnology industry. Invitae has 1,300 more employees than PGDx.

Guardant Health is one of PGDx's top rivals. Guardant Health is a Public company that was founded in Redwood City, California in 2013. Guardant Health operates in the Biotechnology industry. Guardant Health has 422 more employees vs. PGDx.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $16M a good estimate for PGDx's revenue?

Acquisitions

No recent acquisitions found related to PGDx

PGDx Funding History

$500K$3.3M$28.1M$93.4M$210.4M$215.4M$220.2M

Since PGDx was founded in 2010, it has participated in 10 rounds of funding. In total PGDx has raised $220.2M. PGDx's last funding round was on May 2020 for a total of $2.8M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
May 2020
$2.8M
Debt - PPP (CARES Act)
Apr 2020
$2M - $5M

U.S. Small Business Administration.

Debt
Jun 2019
$5M
Equity
Oct 2018
$42M
Series B
Jan 2018
$75M

Total Funding: $220.2M

Since PGDx was founded in 2010, it has participated in 10 rounds of funding. In total PGDx has raised $220.2M. PGDx's last funding round was on May 2020 for a total of $2.8M

Investments

No recent investments found related to PGDx

PGDx News

May 7, 2020Clinical Lab Products

FDA Clears Genomic Profiling Kit for Cancer Diagnosis

PGDx Elio tissue complete increases patient access to precision-based comprehensive genomic profiling... See more »
April 28, 2020TechCrunch

NEA-backed Personal Genome Diagnostics receives FDA clearance for its cancer diagnostic

Personal Genome Diagnostics, the venture-backed developer of a novel diagnostic kit for genomic profi... See more »
April 22, 2020The Business Journals: Baltimore

Baltimore's PGDx taps new CEO

Baltimore-based biotechnology firm Personal Genome Diagnostics Inc. (PGDx) has promoted Megan Bailey ... See more »
February 25, 2020Clinical Lab Products

Personal Genome Diagnostics and Mayo Clinic Collaborate to Enhance Patient Care in Oncology

The collaboration will combine Mayo Clinic's clinical knowledge and expertise in oncology with PGDx's... See more »
January 29, 2020firstwordpharma

Eisai Commences Joint Research And Development Of Cancer Gene Panel Test With Personal Genome Diagnostics Inc. Using Liquid Biopsy To Accelerate Next-Generation Drug Discovery And Development

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered ... See more »
January 8, 2020HIT Consultant Media

Personal Genome Diagnostics, Mayo Clinic Partner to Enhance Patient Care in Oncology

- Together, PGDx and Mayo Clinic will focus on technology optimization and clinical utility studies f... See more »

PGDx Blogs

May 30, 2017Personal Genome Diagnostics Blog

AACR 2017 Quick Glance

From April 1-5, 21,000 scientists gathered in Washington, D.C., for AACR, the largest cancer research... See more »
May 16, 2017Personal Genome Diagnostics Blog

Genomic Predictors of Immunotherapy Response

One of the most cutting-edge pan-cancer biomarkers for response to cancer therapeutics is microsatell... See more »
May 16, 2017Personal Genome Diagnostics Blog

Tumor Evolution: A Resistance Mechanism To Checkpoint Blockade Inhibitors

Tumor cells are readily targeted and destroyed by the body's army of cytotoxic T cells. Normally, ch... See more »
April 10, 2017Personal Genome Diagnostics Blog

Liquid Biopsy: Addressing the need, when tissue is an issue

For oncologists, molecular testing of tissue biopsies currently remains the gold standard for best un... See more »
March 14, 2017Personal Genome Diagnostics Blog

The Fault in Our DNA

"What am I at war with? My cancer. And what is my cancer? My cancer is me. The tumors are made of me... See more »

PGDx Press Releases

June 13, 2016PR Newswire

Personal Genome Diagnostics Co-Founders Named EY Entrepreneur Of The Year 2016® Maryland

BALTIMORE, June 13, 2016 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a provider of advan... See more »
October 28, 2015PR NEWSWIRE

Personal Genome Diagnostics Secures $21.4 Million in Series A Financing Led By New Enterprise Associates

BALTIMORE, Oct. 28, 2015 /PRNewswire/ -- Personal Genome Diagnostics, Inc. (PGDx), a provider of adva... See more »
September 30, 2015PR NEWSWIRE

Personal Genome Diagnostics Collaborates On Nature Study Identifying New Mechanisms Of Response To Anti-EGFR Therapies In Colorectal Cancer

BALTIMORE, Sept. 30, 2015 /PRNewswire/ -- Personal Genome Diagnostics, Inc. (PGDx), a provider of adv... See more »
July 8, 2015PR NEWSWIRE

Personal Genome Diagnostics Collaborates On Study Uncovering New Actionable Mutations And Prognostic Predictors In Pancreatic Cancer

BALTIMORE, July 8, 2015 /PRNewswire/ -- Personal Genome Diagnostics, Inc. (PGDx), a provider of advan... See more »
June 11, 2015PR NEWSWIRE

Personal Genome Diagnostics Launches LungSelect For Non-Invasive Detection Of Clinically Actionable Mutations In Lung Cancer

BALTIMORE, June 11, 2015 /PRNewswire/ -- Personal Genome Diagnostics, Inc. (PGDx), a provider of adva... See more »
May 29, 2015PR NEWSWIRE

Personal Genome Diagnostics Launches ImmunoSelect -R For Identification Of Immunogenic Cancer Mutations To Support Immuno-Oncology Drug Development

BALTIMORE, May 29, 2015 /PRNewswire/ -- Personal Genome Diagnostics, Inc. (PGDx), a provider of advan... See more »
April 15, 2015PR NEWSWIRE

Personal Genome Diagnostics Study Highlights Limitations of Tumor-Only Sequencing for Cancer

BALTIMORE, April 15, 2015 /PRNewswire/ -- Personal Genome Diagnostics, Inc. (PGDx), a provider of adv... See more »

Headquarters

2809 Boston Street Suite 503

Baltimore, Maryland21224

1-443-602-8833

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

PGDx is a biopharmaceutical company that develops and commercializes liquid biopsy genome testing products for the treatment of cancer. PGDx was founded in 2010. PGDx's headquarters is located in Baltimore, Maryland, USA 21224. It has raised 220.2M in...

CEO

PGDx's CEO, Megan Bailey, currently has an approval rating of 82%. PGDx's primary competitors are Biocept, Invitae & Guardant Health.

Website

personalgenome.com

Frequently Asked Questions about PGDx

  1. When was PGDx founded?

    PGDx was founded in 2010
  2. Who is PGDx's CEO?

    PGDx's CEO is Megan Bailey
  3. How much revenue does PGDx generate?

    PGDx generates $16M in revenue
  4. How much funding does PGDx have?

    PGDx has historically raised $220.2M in funding
  1. Where is PGDx's headquarters?

    PGDx's headquarters is in Baltimore Maryland, USA
  2. How many employees does PGDx have?

    PGDx has 200 employees
  3. What sector does PGDx operate in?

    PGDx is in Biotechnology
  4. Who are PGDx's competitors?

    PGDx's top competitors are Biocept, Invitae, Guardant Health